In NSCLC, it has been reported that programmed cell death protein 1 (PD‐1) antibodies promote T cell proliferation and cytokine production,21 and activated CD4+ T cells enhance the efficacy of cytotoxic anticancer drugs both in vivo and in vitro.22 This evidence concerns the gene CD4 and non-small cell lung carcinoma.